A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2006
06/13/2006	US7060429 Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
06/13/2006	US7060308 Caralluma extract products and processes for making the same
06/13/2006	US7060307 Topical composition for heightened sensitivity
06/13/2006	US7060304 Skin whitening compositions containing black cohosh extract
06/13/2006	US7060302 Metal-containing compositions, preparations and uses
06/13/2006	US7060297 Transitional viscoelastics (having non-shear related variable viscosities) contain kappa-carrageenans, potassium and second sulfated polysachharide for protecting or stabilizing eye tissues during surgery
06/13/2006	US7060295 Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
06/13/2006	US7060294 A compressed tablet made of efavirenz, filler/ disintegrant, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent; useful for treating HIV infections and AIDS
06/13/2006	US7060290 Phosphocholine linked prodrug derivatives
06/13/2006	US7060289 Topical glycopyrrolate product
06/13/2006	US7060285 Dispersions for the formulation of slightly or poorly soluble agents
06/13/2006	US7060263 Super absorption Coenzyme Q10
06/13/2006	US7060262 Administering granulocyte colony stimulating factor; Crohn's disease
06/13/2006	US7060259 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
06/13/2006	US7060257 Cosmetic or dermatological light-protective formulation comprising a water-soluble UV filter substance and a benzoxazole derivative
06/13/2006	US7060255 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
06/13/2006	US7060254 Aerosol; heating thin film on solid support; vaporization with air flow
06/13/2006	CA2433288C Process for making amlodipine maleate
06/13/2006	CA2387997C Process for preparing oxazolines from tetrahydrofurans
06/13/2006	CA2380414C Method of cancer treatment
06/13/2006	CA2366623C Resorcinol composition
06/13/2006	CA2362903C Novel sulfofucosylacylglycerol derivatives and use thereof as medicaments
06/13/2006	CA2324590C C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists
06/13/2006	CA2309836C Drug delivery systems utilizing liquid crystal structures
06/13/2006	CA2302601C Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
06/13/2006	CA2268954C Oxadiazoles, processes for their preparation and their use as medicaments
06/13/2006	CA2260777C Pentafluorobenzenesulfonamides and analogs
06/13/2006	CA2247175C Novel erythromycin derivatives, method for preparing same, and use thereof as drugs
06/13/2006	CA2238723C Arylethenesulfonamide derivatives and drug composition containing the same
06/13/2006	CA2237194C Furan- and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
06/13/2006	CA2180008C Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
06/13/2006	CA2155434C Prohormone convertase transformed cells and polypeptide synthesis
06/13/2006	CA2131103C Pyrido[1,2,3-d,e][1,3,4]benzoxadiazine derivatives
06/10/2006	CA2527585A1 New benzothiazine and benzothiadiazine derivatives, their preparation process and the pharmaceutical compounds that contain them
06/08/2006	WO2006131552A1 Alpha-carbolines as cdk-1 inhibitors
06/08/2006	WO2006060819A2 Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
06/08/2006	WO2006060817A1 Pharmaceutical compositions
06/08/2006	WO2006060810A1 Sulfonamide compounds as cysteine protease inhibitors
06/08/2006	WO2006060774A2 Agents that inhibit flavivirus replication and uses thereof
06/08/2006	WO2006060765A2 Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals
06/08/2006	WO2006060762A2 Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
06/08/2006	WO2006060736A2 A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
06/08/2006	WO2006060731A2 Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
06/08/2006	WO2006060730A2 Potassium salt of an hiv integrase inhibitor
06/08/2006	WO2006060712A2 Potassium salt of an hiv integrase inhibitor
06/08/2006	WO2006060711A2 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
06/08/2006	WO2006060702A1 Substitued 3,4-dihydrothieno [2,3-d] pyrmidines as tissue transglutaminase inhibitors
06/08/2006	WO2006060698A1 Nanoparticulate benzothiophene formulations
06/08/2006	WO2006060697A1 Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
06/08/2006	WO2006060676A1 Compositions and methods for treating neoplastic diseases
06/08/2006	WO2006060672A2 Modified release ciprofloxacin compositions
06/08/2006	WO2006060647A1 Methods of treatment and prevention
06/08/2006	WO2006060618A2 Topical nepafenac formulations
06/08/2006	WO2006060617A1 Ascomycin crystalline forms and preparation thereof
06/08/2006	WO2006060615A1 Non-hygroscopic and powdery amorphous pimecrolimus
06/08/2006	WO2006060614A1 Methods for preparing pimecrolimus
06/08/2006	WO2006060580A1 Therapeutic formulations
06/08/2006	WO2006060535A2 Indole derivatives for use as ppar active compounds
06/08/2006	WO2006060507A2 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
06/08/2006	WO2006060494A1 Haloalkyl containing compounds as cysteine protease inhibitors
06/08/2006	WO2006060475A1 Method for treating skin disorders with xanthophylls
06/08/2006	WO2006060470A1 Antioxidant dietary supplement compositions and methods for maintaining healthy skin
06/08/2006	WO2006060464A1 Methods of using temozolomide formulation intrathecally in the treatment of cancers
06/08/2006	WO2006060461A1 Substituted piperazines as cb1 antagonists
06/08/2006	WO2006060460A1 Treating acute exacerbations of asthma using a ketolide
06/08/2006	WO2006060424A2 Inducible nitric oxide synthase dimerization inhibitors
06/08/2006	WO2006060419A2 Biomarkers for pre-selection of patients for anti-igf1r therapy
06/08/2006	WO2006060382A2 Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
06/08/2006	WO2006060381A2 N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
06/08/2006	WO2006060346A2 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
06/08/2006	WO2006060344A2 5-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
06/08/2006	WO2006060331A1 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
06/08/2006	WO2006060318A2 Quinolines and quinazoline analogs and their use as medicaments for treating cancer
06/08/2006	WO2006060301A2 Starch derivatives and other derivatives, production processes therefor, and wound healing applications therefor
06/08/2006	WO2006060211A2 Pyrazole derivatives for the treatment of sexual dysfunction
06/08/2006	WO2006060203A2 Imidazole derivatives for the treatment of dementia and related disorders
06/08/2006	WO2006060202A2 Imidazole derivatives for the treatment of psychiatric disorders
06/08/2006	WO2006060201A2 Pyrazole derivatives for the treatment of psychiatric disorders
06/08/2006	WO2006060199A2 Imidazole derivatives for the treatment of sexual dysfunction
06/08/2006	WO2006060198A1 Translation lookaside buffer (tlb) access supression for intra-page program counter relative or absolute address branch instructions
06/08/2006	WO2006060196A2 Use of rottlerin and its derivatives as activators of bk channel for therapy of hypertension and related disorders
06/08/2006	WO2006060194A1 Pyrimidine compounds and uses thereof
06/08/2006	WO2006060192A2 Pyrazole derivatives
06/08/2006	WO2006060190A2 Imidazole derivatives
06/08/2006	WO2006060186A2 Pyrazole derivatives for the treatment of dementia and related disorders
06/08/2006	WO2006060177A1 Method for treating hiv infection through co-administration of tipranavir and gw873140
06/08/2006	WO2006060175A1 Method for treating hiv infection through co-administration of tipranavir and sch-417690
06/08/2006	WO2006060159A1 Method for treating hiv infection through co-administration of tipranavir and gw695634
06/08/2006	WO2006060145A2 Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives
06/08/2006	WO2006060127A2 COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
06/08/2006	WO2006060122A2 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
06/08/2006	WO2006060120A2 Liposomal formulation for oral administration of glutathione (reduced)
06/08/2006	WO2006060117A2 Methods for inhibition of nkt cells
06/08/2006	WO2006060109A1 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
06/08/2006	WO2006060108A1 N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
06/08/2006	WO2006060084A2 Coadministration of tigecycline and digoxin
06/08/2006	WO2006060082A1 Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
06/08/2006	WO2006060079A2 Methods and compositions for treating nephrogenic diabetes insipidus
06/08/2006	WO2006059945A1 Novel compounds
06/08/2006	WO2006059897A1 Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae

1 ... 4223 4224 4225 4226 4227 4228 4229 4230 4231 4232 4233 4234 4235 4236 4237 4238 4239 4240 4241 4242 4243 ... 7860